Results 201 to 210 of about 220,644 (260)
Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang +5 more
wiley +1 more source
Activation of mitophagy antagonizes high uric acid-induced hepatic lipid accumulation. [PDF]
Chen J +18 more
europepmc +1 more source
ABSTRACT Accurate differentiation between benign and malignant focal liver lesions (FLLs) remains a major diagnostic challenge. Vasomics, an emerging discipline, classifies vascular phenotypes into anatomical, biomechanical, biochemical, pathophysiological, and composite categories. Sono‐Vasomics, the ultrasound‐based subset, leverages super‐resolution
Yijie Qiu +5 more
wiley +1 more source
Mediating Effect of Serum Uric Acid in the Association Between Nocturia and Mortality. [PDF]
Kim SJ +5 more
europepmc +1 more source
Machine learning‐based predictive models outperform traditional risk scores in hemodialysis patients with comorbid urolithiasis by capturing nonlinear, dialysis‐specific interactions. These approaches enable more accurate prediction of stone recurrence, sepsis, hospitalization, and mortality, supporting personalized risk stratification and precision ...
Dipal Chaulagain +4 more
wiley +1 more source
Predictive value of uric acid and lactate dehydrogenase for maternal morbidity in preeclampsia: a retrospective case-control study. [PDF]
Emral ÇK, Güngör ES, Kizildemir YZ.
europepmc +1 more source
Farnesoid X receptor prevents hyperuricemia via activating ATP‐binding cassette subfamily G member 2
Farnesoid X receptor (FXR) activation reduces serum uric acid levels by upregulating the intestinal urate transporter ATP‐binding cassette subfamily G member 2 (ABCG2). These findings uncover a novel metabolic pathway for urate excretion and suggest that FXR agonists (e.g., obeticholic acid), represent a promising therapeutic strategy for the treatment
Rui Li +5 more
wiley +1 more source
Uric acid as a potential biomarker for cardiomyopathy in dystrophinopathy. [PDF]
Li Z +8 more
europepmc +1 more source
SERS‐Based Nano‐ and Microsystems Toward Biomedical Applications
This review provides a current overview of nano‐ and microscale SERS‐based devices, encompassing all aspects from material design to practical applications. We highlight controlled SERS‐active architectures, including patterned substrates, nanorods, microspheres, micromotors, and microneedles, as well as combinations of these microfluidic systems.
Gohar Soufi +14 more
wiley +1 more source
A meta-analysis of serum uric acid and diabetic nephropathy risk in type 2 diabetes. [PDF]
Zhao J, Zhao L.
europepmc +1 more source

